Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamunex-C in HMGCR Necrotizing Myopathy
NCT04450654Phase 2Withdrawn
- Sponsor
- University of Washington
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of immune globulin in immune-mediated necrotizing myopathy (IMNM), sponsored by University of Washington. Planned start May 2022; status: withdrawn.
02
Drugs
immune globulin
03
Conditions
immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on NCT04450654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04450654.